Several observational studies consistently demonstrate independent associations between FGF23 and accelerated CKD progression [9], left ventricular hypertrophy in dialysis and predialysis patients [10], and increased mortality risk in CKD and hemodialysis patients and kidney transplant recipients [10–14]. This evidence concerns the gene FGF23 and chronic kidney disease.